STEVE'S JOB: RESTART APPLE
(8 of 8)
Unlike Apple, Pixar is expanding, having gone from 175 people to 375 this year alone. The original Richmond studio now has an outpost working busily on a direct-to-video sequel to Toy Story, and there's a mysterious third major project in the works too. Jobs has plans for a new studio, to sprawl on 16 acres in industrial Emeryville, near Berkeley. Interior plans have been carefully drawn--before the exterior--to ensure a cross-pollination of ideas. And of course, he says, all the offices will be the same size.
For the next few months, however, Steve Jobs' main job will be Apple. The Microsoft Death Star may be rotating in friendly orbit, but Jobs must still find a new leader for the Mac troops. Then he can resume being a Hollywood mogul and a model dad, right? Even after this amazing week, Jobs insists he will pass the diskette to a new generation and then stand aside to let it run the program. But Apple is his first child, and you know how hard it is to let the first child go. Watch for the sequel here.
--With reporting by David S. Jackson/San Francisco and Valerie Marchant/New York
Most Popular »
- Five Things the U.S. Can Learn from China
- World Leaders Put Off a Climate Change Treaty
- The Prisoner Review: A Pretentious Reimagining
- Good and Bad News for Boxing: Only One Pacquiao
- China Investigates Deaths After Swine Flu Shot
- Box Office Weekend: 2012 Masters Disaster
- Does Mexico City Need a Red-Light District?
- The Meaning and Mythos of Manny Pacquiao
- YouTube Effect: Making Money From Viral Videos
- Happiness Paradox: Why Are Americans So Cheery?
- Five Things the U.S. Can Learn from China
- Good and Bad News for Boxing: Only One Pacquiao
- Happiness Paradox: Why Are Americans So Cheery?
- Beijing: 10 Things to Do in 24 Hours
- Does Mexico City Need a Red-Light District?
- Why Legalizing Marijuana Makes Sense
- Time Essay: The Death Penalty: Cruel and Unusual?
- Now It's Official: There Is Water on the Moon
- Armed Forces: The Men in the Green Berets
- In a Malaria Hot Spot, Resistance to a Key Drug







RSS